Ensign Peak Advisors’s Akero Therapeutics AKRO Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $10.1M | Buy |
188,409
+33,365
| +22% | +$1.78M | 0.02% | 470 |
|
|
2025
Q1 | $6.28M | Hold |
155,044
| – | – | 0.01% | 579 |
|
|
2024
Q4 | $4.31M | Hold |
155,044
| – | – | 0.01% | 685 |
|
|
2024
Q3 | $4.45M | Sell |
155,044
-82,450
| -35% | -$2.37M | 0.01% | 661 |
|
|
2024
Q2 | $5.57M | Buy |
237,494
+4,950
| +2% | +$116K | 0.01% | 594 |
|
|
2024
Q1 | $5.87M | Sell |
232,544
-720
| -0.3% | -$18.2K | 0.01% | 578 |
|
|
2023
Q4 | $5.45M | Buy |
233,264
+650
| +0.3% | +$15.2K | 0.01% | 607 |
|
|
2023
Q3 | $11.8M | Buy |
232,614
+55,000
| +31% | +$2.78M | 0.03% | 347 |
|
|
2023
Q2 | $8.29M | Buy |
177,614
+2,050
| +1% | +$95.7K | 0.02% | 470 |
|
|
2023
Q1 | $6.72M | Buy |
175,564
+12,300
| +8% | +$471K | 0.01% | 493 |
|
|
2022
Q4 | $8.95M | Sell |
163,264
-6,770
| -4% | -$371K | 0.02% | 439 |
|
|
2022
Q3 | $5.79M | Buy |
170,034
+98,543
| +138% | +$3.36M | 0.01% | 490 |
|
|
2022
Q2 | $676K | Buy |
71,491
+46,206
| +183% | +$437K | ﹤0.01% | 1317 |
|
|
2022
Q1 | $359K | Hold |
25,285
| – | – | ﹤0.01% | 1688 |
|
|
2021
Q4 | $535K | Hold |
25,285
| – | – | ﹤0.01% | 1602 |
|
|
2021
Q3 | $565K | Hold |
25,285
| – | – | ﹤0.01% | 1596 |
|
|
2021
Q2 | $628K | Hold |
25,285
| – | – | ﹤0.01% | 1547 |
|
|
2021
Q1 | $733K | Hold |
25,285
| – | – | ﹤0.01% | 1517 |
|
|
2020
Q4 | $652K | Buy |
25,285
+5,964
| +31% | +$154K | ﹤0.01% | 1543 |
|
|
2020
Q3 | $595K | Sell |
19,321
-7,881
| -29% | -$243K | ﹤0.01% | 1485 |
|
|
2020
Q2 | $678K | Buy |
27,202
+11,933
| +78% | +$297K | ﹤0.01% | 1400 |
|
|
2020
Q1 | $324K | Sell |
15,269
-8,554
| -36% | -$182K | ﹤0.01% | 1472 |
|
|
2019
Q4 | $529K | Buy |
+23,823
| New | +$529K | ﹤0.01% | 1499 |
|